Top

Published in:

01-10-2013 | Original Article

Mast cells expressing interleukin 17 in the muscularis propria predict a favorable prognosis in esophageal squamous cell carcinoma

Authors: Bo Wang, Lian Li, Yuan Liao, Jinqing Li, Xingjuan Yu, Yi Zhang, Jing Xu, Huilan Rao, Shupeng Chen, Lanjun Zhang, Limin Zheng

Published in: Cancer Immunology, Immunotherapy | Issue 10/2013

Abstract

The proinflammatory cytokine interleukin 17 (IL-17) is considered to play a crucial role in diverse human tumors; however, its role in disease progression remains controversial. This study investigated the cellular source and distribution of IL-17 in esophageal squamous cell carcinoma (ESCC) in situ and determined its prognostic value. Immunohistochemistry, immunofluorescence and immunoelectron microscopy were used to identify IL-17-expressing cells in ESCC tissues, paying particular attention to their anatomic localization. Kaplan–Meier analysis and Cox proportional hazards regression models were applied to estimate overall survival in 215 ESCC patients with long-term follow-up (>10 years). The results showed that mast cells, but not T cells or macrophages, were the predominant cell type expressing IL-17 in ESCC tissues. Unexpectedly, these IL-17⁺ cells were highly enriched in the muscularis propria rather than the corresponding tumor nest (p < 0.0001). The density of IL-17⁺ cells in muscularis propria was inversely associated with tumor invasion (p = 0.016) and served as an independent predictor of favorable survival (p = 0.007). Moreover, the levels of IL-17⁺ cells in muscularis propria were positively associated with the density of effector CD8⁺ T cells and activated macrophages in the same area (both p < 0.0001). This finding suggested that mast cells may play a significant role in tumor immunity by releasing IL-17 at a previously unappreciated location, the muscularis propria, in ESCC tissues, which could serve as a potential prognostic marker and a novel therapeutic target for ESCC.

Available only for authorised users

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90. doi:10.3322/caac.20107 PubMedCrossRef

Enzinger PC, Mayer RJ (2003) Esophageal cancer. N Engl J Med 349(23):2241–2252. doi:10.1056/NEJMra035010 PubMedCrossRef

Cooper SL, Russo JK, Chin S (2012) Definitive chemoradiotherapy for esophageal carcinoma. Surg Clin North Am 92(5):1213–1248. doi:10.1016/j.suc.2012.07.013 PubMedCrossRef

Rice TW, Zuccaro G Jr, Adelstein DJ, Rybicki LA, Blackstone EH, Goldblum JR (1998) Esophageal carcinoma: depth of tumor invasion is predictive of regional lymph node status. Ann Thorac Surg 65(3):787–792PubMedCrossRef

Mueller MM, Fusenig NE (2004) Friends or foes—bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 4(11):839–849. doi:10.1038/nrc1477 PubMedCrossRef

Hanahan D, Coussens LM (2012) Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21(3):309–322. doi:10.1016/j.ccr.2012.02.022 PubMedCrossRef

Fridman WH, Pages F, Sautes-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12(4):298–306. doi:10.1038/nrc3245 PubMedCrossRef

Cho Y, Miyamoto M, Kato K, Fukunaga A, Shichinohe T, Kawarada Y, Hida Y, Oshikiri T, Kurokawa T, Suzuoki M, Nakakubo Y, Hiraoka K, Murakami S, Shinohara T, Itoh T, Okushiba S, Kondo S, Katoh H (2003) CD4 + and CD8 + T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res 63(7):1555–1559PubMed

Liu J, Lu G, Li Z, Tang F, Liu Y, Cui G (2010) Distinct compartmental distribution of mature and immature dendritic cells in esophageal squamous cell carcinoma. Pathol Res Pract 206(9):602–606. doi:10.1016/j.prp.2010.03.011 PubMedCrossRef

10.

Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454(7203):436–444. doi:10.1038/nature07205 PubMedCrossRef

11.

Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140(6):883–899. doi:10.1016/j.cell.2010.01.025 PubMedCrossRef

12.

Murugaiyan G, Saha B (2009) Protumor vs antitumor functions of IL-17. J Immunol 183(7):4169–4175. doi:10.4049/jimmunol.0901017 PubMedCrossRef

13.

Zou W, Restifo NP (2010) T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 10(4):248–256. doi:10.1038/nri2742 PubMedCrossRef

14.

Huang G, Wang Y, Chi H (2012) Regulation of TH17 cell differentiation by innate immune signals. Cell Mol Immunol 9(4):287–295. doi:10.1038/cmi.2012.10 PubMedCrossRef

15.

Cua DJ, Tato CM (2010) Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol 10(7):479–489. doi:10.1038/nri2800 PubMedCrossRef

16.

de Boer OJ, van der Meer JJ, Teeling P, van der Loos CM, Idu MM, van Maldegem F, Aten J, van der Wal AC (2010) Differential expression of interleukin-17 family cytokines in intact and complicated human atherosclerotic plaques. J Pathol 220(4):499–508. doi:10.1002/path.2667 PubMed

17.

Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP, Wu C, Zheng L (2009) Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med 206(6):1327–1337. doi:10.1084/jem.20082173 PubMedCrossRef

18.

Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795):1960–1964. doi:10.1126/science.1129139 PubMedCrossRef

19.

Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A, Hallett M, Park M (2008) Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14(5):518–527. doi:10.1038/nm1764 PubMedCrossRef

20.

Zhang JP, Yan J, Xu J, Pang XH, Chen MS, Li L, Wu C, Li SP, Zheng L (2009) Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 50(5):980–989. doi:10.1016/j.jhep.2008.12.033 PubMedCrossRef

21.

Kuang DM, Peng C, Zhao Q, Wu Y, Chen MS, Zheng L (2010) Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells. Hepatology 51(1):154–164. doi:10.1002/hep.23291 PubMedCrossRef

22.

Kuang DM, Zhao Q, Wu Y, Peng C, Wang J, Xu Z, Yin XY, Zheng L (2011) Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J Hepatol 54(5):948–955. doi:10.1016/j.jhep.2010.08.041 PubMedCrossRef

23.

Lin SH, Chang JY (2010) Esophageal cancer: diagnosis and management. Chin J Cancer 29(10):843–854PubMedCrossRef

24.

Zhu ZH, Sun BY, Ma Y, Shao JY, Long H, Zhang X, Fu JH, Zhang LJ, Su XD, Wu QL, Ling P, Chen M, Xie ZM, Hu Y, Rong TH (2009) Three immunomarker support vector machines-based prognostic classifiers for stage IB non-small-cell lung cancer. J Clin Oncol 27(7):1091–1099. doi:10.1200/JCO.2008.16.6991 PubMedCrossRef

25.

Ding T, Xu J, Wang F, Shi M, Zhang Y, Li SP, Zheng L (2009) High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection. Hum Pathol 40(3):381–389. doi:10.1016/j.humpath.2008.08.011 PubMedCrossRef

26.

Takahashi N, Vanlaere I, de Rycke R, Cauwels A, Joosten LA, Lubberts E, van den Berg WB, Libert C (2008) IL-17 produced by Paneth cells drives TNF-induced shock. J Exp Med 205(8):1755–1761. doi:10.1084/jem.20080588 PubMedCrossRef

27.

Lin AM, Rubin CJ, Khandpur R, Wang JY, Riblett M, Yalavarthi S, Villanueva EC, Shah P, Kaplan MJ, Bruce AT (2011) Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol 187(1):490–500. doi:10.4049/jimmunol.1100123 PubMedCrossRef

28.

Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, Basham B, Smith K, Chen T, Morel F, Lecron JC, Kastelein RA, Cua DJ, McClanahan TK, Bowman EP, de Waal Malefyt R (2007) Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 8(9):950–957. doi:10.1038/ni1497 PubMedCrossRef

29.

Hueber AJ, Asquith DL, Miller AM, Reilly J, Kerr S, Leipe J, Melendez AJ, McInnes IB (2010) Mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol 184(7):3336–3340. doi:10.4049/jimmunol.0903566 PubMedCrossRef

30.

Zhu X, Mulcahy LA, Mohammed RA, Lee AH, Franks HA, Kilpatrick L, Yilmazer A, Paish EC, Ellis IO, Patel PM, Jackson AM (2008) IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res 10(6):R95. doi:10.1186/bcr2195 PubMedCrossRef

31.

Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, Bamba T, Fujiyama Y (2003) Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52(1):65–70PubMedCrossRef

32.

Abraham SN, St John AL (2010) Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol 10(6):440–452. doi:10.1038/nri2782 PubMedCrossRef

33.

Galli SJ, Grimbaldeston M, Tsai M (2008) Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat Rev Immunol 8(6):478–486. doi:10.1038/nri2327 PubMedCrossRef

34.

Asano K, Nabeyama A, Miyake Y, Qiu CH, Kurita A, Tomura M, Kanagawa O, Fujii S, Tanaka M (2011) CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens. Immunity 34(1):85–95. doi:10.1016/j.immuni.2010.12.011 PubMedCrossRef

35.

Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH, Chang A, Coukos G, Liu R, Zou W (2009) Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114(6):1141–1149. doi:10.1182/blood-2009-03-208249 PubMedCrossRef

36.

Khazaie K, Blatner NR, Khan MW, Gounari F, Gounaris E, Dennis K, Bonertz A, Tsai FN, Strouch MJ, Cheon E, Phillips JD, Beckhove P, Bentrem DJ (2011) The significant role of mast cells in cancer. Cancer Metastasis Rev 30(1):45–60. doi:10.1007/s10555-011-9286-z PubMedCrossRef

37.

Kalesnikoff J, Galli SJ (2008) New developments in mast cell biology. Nat Immunol 9(11):1215–1223. doi:10.1038/ni.f.216 PubMedCrossRef

38.

Welsh TJ, Green RH, Richardson D, Waller DA, O’Byrne KJ, Bradding P (2005) Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol 23(35):8959–8967. doi:10.1200/JCO.2005.01.4910 PubMedCrossRef

39.

Noordenbos T, Yeremenko N, Gofita I, van de Sande M, Tak PP, Canete JD, Baeten D (2012) Interleukin-17-positive mast cells contribute to synovial inflammation in spondyloarthritis. Arthr Rheum 64(1):99–109. doi:10.1002/art.33396 CrossRef

40.

Connor SJ, Paraskevopoulos N, Newman R, Cuan N, Hampartzoumian T, Lloyd AR, Grimm MC (2004) CCR2 expressing CD4 + T lymphocytes are preferentially recruited to the ileum in Crohn’s disease. Gut 53(9):1287–1294. doi:10.1136/gut.2003.028225 PubMedCrossRef

41.

Villablanca EJ, Cassani B, von Andrian UH, Mora JR (2011) Blocking lymphocyte localization to the gastrointestinal mucosa as a therapeutic strategy for inflammatory bowel diseases. Gastroenterology 140(6):1776–1784. doi:10.1053/j.gastro.2011.02.015 PubMedCrossRef

42.

Flores-Langarica A, Meza-Perez S, Calderon-Amador J, Estrada-Garcia T, Macpherson G, Lebecque S, Saeland S, Steinman RM, Flores-Romo L (2005) Network of dendritic cells within the muscular layer of the mouse intestine. Proc Natl Acad Sci U S A 102(52):19039–19044. doi:10.1073/pnas.0504253102 PubMedCrossRef

43.

Lv L, Pan K, Li XD, She KL, Zhao JJ, Wang W, Chen JG, Chen YB, Yun JP, Xia JC (2011) The accumulation and prognosis value of tumor infiltrating IL-17 producing cells in esophageal squamous cell carcinoma. PLoS ONE 6(3):e18219. doi:10.1371/journal.pone.0018219 PubMedCrossRef

44.

Sfanos KS, Bruno TC, Maris CH, Xu L, Thoburn CJ, DeMarzo AM, Meeker AK, Isaacs WB, Drake CG (2008) Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res: Off J Am Assoc Cancer Res 14(11):3254–3261. doi:10.1158/1078-0432.CCR-07-5164 CrossRef

45.

Jovanovic DV, Di Battista JA, Martel-Pelletier J, Jolicoeur FC, He Y, Zhang M, Mineau F, Pelletier JP (1998) IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol 160(7):3513–3521PubMed

Title: Mast cells expressing interleukin 17 in the muscularis propria predict a favorable prognosis in esophageal squamous cell carcinoma
Authors: Bo Wang
Lian Li
Yuan Liao
Jinqing Li
Xingjuan Yu
Yi Zhang
Jing Xu
Huilan Rao
Shupeng Chen
Lanjun Zhang
Limin Zheng
Publication date: 01-10-2013
Publisher: Springer Berlin Heidelberg
Published in: Cancer Immunology, Immunotherapy / Issue 10/2013
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-013-1460-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2013

Dendritic cell phenotype can be improved by certain chemotherapies and is associated with alterations to p21waf1/cip1

Late divergence of survival curves in cancer immunotherapy trials: interpretation and implications

Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFβ1

Clinical-scale selection and viral transduction of human naïve and central memory CD8+ T cells for adoptive cell therapy of cancer patients

Efficacy of postoperative adjuvant transfusion of cytokine-induced killer cells combined with chemotherapy in patients with colorectal cancer

Reduced expression of NGEP is associated with high-grade prostate cancers: a tissue microarray analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer